Stock Events

Stock Events

Grace Therapeutics 

€0
137
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

23JunExpected
Q4 2025
Next
-0.24
-0.2
-0.16
-0.12
Expected EPS
-0.19543100000000002
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow L8S.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Amarin
AMRN
Mkt Cap315.59M
Amarin Corporation plc focuses on the development and commercialization of therapeutics for cardiovascular health, directly competing with Acasti Pharma's focus on omega-3 phospholipids for similar conditions.
Astrazeneca
AZN
Mkt Cap283.47B
AstraZeneca PLC, a large pharmaceutical company, has a diverse portfolio that includes treatments for cardiovascular diseases, competing with Acasti Pharma's cardiovascular focus.
Pfizer
PFE
Mkt Cap146.36B
Pfizer Inc. has a broad range of products including treatments for cardiovascular diseases, making it a competitor to Acasti Pharma in the cardiovascular therapeutic area.
Merck
MRK
Mkt Cap275.09B
Merck & Co., Inc. offers a wide range of healthcare solutions, including cardiovascular disease treatments, competing with Acasti Pharma's product offerings.
Novartis
NVS
Mkt Cap278.64B
Novartis AG, with its extensive research and development in cardiovascular diseases, competes with Acasti Pharma in the market for cardiovascular health solutions.
GSK
GSK
Mkt Cap101.2B
GlaxoSmithKline plc has a diversified portfolio that includes cardiovascular drugs, making it a competitor to Acasti Pharma in the cardiovascular space.
Abbvie
ABBV
Mkt Cap356.49B
AbbVie Inc. engages in the discovery, development, manufacture, and sale of a broad line of pharmaceuticals, including those for cardiovascular diseases, competing with Acasti Pharma.
AMGEN
AMGN
Mkt Cap179.12B
Amgen Inc. focuses on human therapeutics, including cardiovascular disease treatments, which positions it as a competitor to Acasti Pharma.
Bristol-Myers Squibb
BMY
Mkt Cap114.68B
Bristol-Myers Squibb Company offers a wide range of prescription pharmaceuticals in several therapeutic areas, including cardiovascular diseases, competing with Acasti Pharma's focus.

About

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Show more...
CEO
Janelle D'Alvise
Employees
32
Country
Canada
ISIN
US00439U1043

Listings

F
DE
A1P0.F
STU
DE
L8S.STU
XNAS
US
GRCE
F
DE
L8S.F

0 Comments

Share your thoughts

FAQ

What is Grace Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Grace Therapeutics stocks are traded under the ticker L8S.STU.
When is the next Grace Therapeutics earnings date?▼
Grace Therapeutics is going to release the next earnings report on June 23, 2026.
What were Grace Therapeutics earnings last quarter?▼
L8S.STU earnings for the last quarter are -0.12 EUR per share, whereas the estimation was -0.24 EUR resulting in a +50% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Grace Therapeutics have?▼
As of May 11, 2026, the company has 32 employees.
In which sector is Grace Therapeutics located?▼
Grace Therapeutics operates in the Technology sector.
When did Grace Therapeutics complete a stock split?▼
Grace Therapeutics has not had any recent stock splits.
Where is Grace Therapeutics headquartered?▼
Grace Therapeutics is headquartered in Laval, Canada.